Quanterix is a Massachusetts company with an ultra-sensitive, versatile Covid-19 antigen test, and they are also the company behind the digital health solution Simoa.
Quanterix is a Massachusetts-based medical company that has developed a laboratory Covid-19 antigen test that uses an ultra-sensitive single-molecule assay to analyze a number of sample types, including nasal swabs, saliva, or finger-prick blood samples. Prior to the outbreak of Covid-19, Quanterix released the digital health solution Simoa, which allows researchers to closely examine critical biomarkers of infectious diseases.
The company focuses on early detection, better prognoses, and enhanced treatment methods. Quanterix’s technology has applications in a range of different therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. The company’s mission is “To change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease.”
In July of 2020, it was reported that Quanterix’s Simoa technology was powering new insights into Covid-19 immune response and revealing new indicators of the disease’s severity. Quanterix’s CEO and Chairman Kevin Hrusovsky announced: “Through our collaborations with Powering Precision Health (PPH)’s global network and leading experts on the frontlines of the pandemic response, we’ve learned that our ultra-sensitive Simoa assays act like ‘a radar system’ for important inflammatory molecules and can be used to predict disease progression and cytokine storms that traditional systems cannot detect.” Detecting patient reaction to Covid-19 is important because one in five will develop what is known as a “critical” reaction to the disease.